CA3140173A1 - Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists - Google Patents

Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists Download PDF

Info

Publication number
CA3140173A1
CA3140173A1 CA3140173A CA3140173A CA3140173A1 CA 3140173 A1 CA3140173 A1 CA 3140173A1 CA 3140173 A CA3140173 A CA 3140173A CA 3140173 A CA3140173 A CA 3140173A CA 3140173 A1 CA3140173 A1 CA 3140173A1
Authority
CA
Canada
Prior art keywords
group
substituted
alkyl
halogen
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3140173A
Other languages
English (en)
French (fr)
Inventor
Belew Mekonnen
Hemantbhai Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hager Biosciences LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3140173A1 publication Critical patent/CA3140173A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3140173A 2019-06-04 2020-06-03 Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists Pending CA3140173A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962856822P 2019-06-04 2019-06-04
US62/856,822 2019-06-04
PCT/US2020/035851 WO2020247447A1 (en) 2019-06-04 2020-06-03 Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists

Publications (1)

Publication Number Publication Date
CA3140173A1 true CA3140173A1 (en) 2020-12-10

Family

ID=73651984

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3140173A Pending CA3140173A1 (en) 2019-06-04 2020-06-03 Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists

Country Status (9)

Country Link
US (2) US20220315602A1 (enExample)
EP (1) EP3972587A4 (enExample)
JP (1) JP7837120B2 (enExample)
KR (1) KR20220016919A (enExample)
CN (1) CN114340616A (enExample)
AU (1) AU2020288559C1 (enExample)
CA (1) CA3140173A1 (enExample)
SG (1) SG11202112828SA (enExample)
WO (1) WO2020247447A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022534704A (ja) 2019-06-04 2022-08-03 ヘイガー バイオサイエンシズ，エルエルシー オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法
KR20220119653A (ko) 2019-12-20 2022-08-30 테나야 테라퓨틱스, 인코포레이티드 플루오로알킬-옥사디아졸 및 이의 용도
US20240252502A1 (en) 2021-05-04 2024-08-01 Tenaya Therapeutics, Inc. Hdac6 inhibitors for treatment of metabolic disease and hfpef
JP2025530768A (ja) * 2022-09-01 2025-09-17 ヘイガー バイオサイエンシズ，エルエルシー 神経疾患および精神疾患の治療のための、オレキシン受容体およびカッパオピオイド受容体に対する二重調節剤としてのピラゾール誘導体およびイミダゾール誘導体、組成物、ならびに治療法
EP4471034A4 (en) * 2022-11-23 2025-06-18 Jiangsu NHWA Pharmaceutical Co., Ltd DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C PYRROL METHYL KETONE DERIVATIVE AND ITS USE
GB202311281D0 (en) 2023-07-21 2023-09-06 Bial Portela & Ca Sa Orexin receptor antagonists
GB202311280D0 (en) 2023-07-21 2023-09-06 Bial Portela & Ca Sa Orexin receptor antagonists
CN117169393B (zh) * 2023-11-03 2024-03-19 杭州湃肽生化科技有限公司 一种植物组织中环肽的检测方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
SI1836211T1 (sl) * 2004-12-21 2010-04-30 Pfizer Prod Inc Makrolidi
AR067665A1 (es) * 2007-07-27 2009-10-21 Actelion Pharmaceuticals Ltd Derivados de trans-3- aza-biciclo ( 3.1.0) hexano
EP2630138B1 (en) * 2010-10-21 2015-06-03 Bayer Intellectual Property GmbH 1-(heterocyclic carbonyl)-2-substituted pyrrolidines and their use as fungicides
EP2730573A4 (en) * 2011-07-05 2014-12-03 Taisho Pharmaceutical Co Ltd METHYLPIPERIDINDERIVAT
US9242995B2 (en) * 2011-10-25 2016-01-26 Merck Sharp & Dohme Corp. Isoxazolopyridine orexin receptor antagonists
JP6346862B2 (ja) * 2012-02-07 2018-06-20 エオラス セラピューティクス， インコーポレイテッド オレキシンレセプターアンタゴニストとしての置換プロリン／ピペリジン
EP3187497A4 (en) * 2014-08-26 2018-02-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
MA53721A (fr) * 2018-09-28 2021-09-15 Janssen Pharmaceutica Nv Modulateurs de la monoacylglycérol lipase
JP2022534704A (ja) * 2019-06-04 2022-08-03 ヘイガー バイオサイエンシズ，エルエルシー オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法

Also Published As

Publication number Publication date
EP3972587A1 (en) 2022-03-30
JP7837120B2 (ja) 2026-03-30
KR20220016919A (ko) 2022-02-10
AU2020288559B2 (en) 2025-04-17
SG11202112828SA (en) 2021-12-30
AU2020288559A1 (en) 2022-01-20
US20220315602A1 (en) 2022-10-06
WO2020247447A1 (en) 2020-12-10
EP3972587A4 (en) 2023-01-18
CN114340616A (zh) 2022-04-12
US20240400580A1 (en) 2024-12-05
US12275744B2 (en) 2025-04-15
JP2022534709A (ja) 2022-08-03
AU2020288559A8 (en) 2022-02-03
AU2020288559C1 (en) 2025-07-24

Similar Documents

Publication Publication Date Title
US12275744B2 (en) Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
EP3762380B1 (en) Phenylpyrrolidinone formyl peptide 2 receptor agonists
AU2020286381B2 (en) Imidazolo derivatives, compositions and methods as orexin antagonists
EP2864318B1 (en) 2-aminopyrazine derivatives as csf-1r kinase inhibitors
AU2016366211B2 (en) Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
CA3129067A1 (en) Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
EP3715341A1 (en) Halo-allylamine ssao/vap-1 inhibitor and use thereof
JP2014524886A (ja) カリウムチャネル遮断剤としてのアミン誘導体
JP2021522253A (ja) 化合物及びその使用
US10654802B2 (en) Indoline derivatives and method for using and producing the same
EP2524912A1 (en) Amine derivatives
WO2026106499A1 (en) Orexin receptor antagonists: 2-azabicyclic compounds
AU2023329899A1 (en) Substituted pyrazoles and imidazoles as orexin receptor antagonists composition, methods for treating neurological and psychiatric disorders
EP2679585A1 (en) Glycine transport inhibitor
HK40028252A (en) Halo-allylamine ssao/vap-1 inhibitor and use thereof
TW202115023A (zh) 新型細胞凋亡訊號調節激酶1抑制劑
US20260070922A1 (en) Pyrazole and imidazole derivatives as dual orexin and kappa-opioid receptors modulators composition, methods for treating neurological and psychiatric disorders

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240527

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250603

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251002

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251118

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260708

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260715